Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.

CONCLUSION: HQ-free, retinol-free CTB and HQ 4% both are effective and well-tolerated in the treatment of moderate facial melasma in FST III–VI. J Drugs Dermatol. 2020;19(9):822-827. doi:10.36849/JDD.2020.5353. PMID: 33026755 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33026755?dopt=Abstract

Source: Journal of Drugs in Dermatology - October 9, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research